Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis

Published:2021-03 Issue: Volume:85 Page:6-12
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

Li Ting,Zhang Guo-Qian,Li Yue,Dong Shu-An,Wang Nan,Yi Ming,Qi Yuan,Zhai Hui,Yang Li,Shi Fu-Dong,Yang Chun-Sheng

Funder

National Key Clinical Specialty Discipline Construction Program of China

Tianjin Medical University

Publisher

Elsevier BV

Subject

Physiology (medical),Neurology (clinical),Neurology,General Medicine,Surgery

Reference35 articles.

1. Myasthenia gravis;Longo;N Engl J Med,2016

2. Rituximab in treatment-refractory myasthenia gravis;Silvestri;JAMA Neurol,2017

3. Immunotherapy in myasthenia gravis in the era of biologics;Dalakas;Nat Rev Neurol,2019

4. Long-lasting treatment effect of rituximab in MuSK myasthenia;Diaz-Manera;Neurology,2012

5. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients;Illa;J Neuroimmunol,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities;Frontiers in Pharmacology;2024-05-27

2. Treating myasthenia gravis beyond the eye clinic;Eye;2024-05-24

3. Myasthenia Gravis and Other Immune-Mediated Disorders of the Neuromuscular Junction;Neuroimmune Diseases;2024

4. Myasthenia Gravis – a new era of treatment options;Advances in Clinical Neuroscience & Rehabilitation;2024

5. Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3